STOCK TITAN

ProKidney Corp. - $PROK STOCK NEWS

Welcome to our dedicated page for ProKidney news (Ticker: $PROK), a resource for investors and traders seeking the latest updates and insights on ProKidney stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ProKidney's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ProKidney's position in the market.

Rhea-AI Summary
ProKidney Corp. CEO to participate in fireside chat at Morgan Stanley Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
conferences
-
Rhea-AI Summary
ProKidney Corp. announces financial results for Q2 2023, advances REACT development programs, and purchases facility in Greensboro. Cash and marketable securities total $446.1 million. R&D expenses increase to $26.4 million. G&A expenses increase to $13.5 million. Net loss before noncontrolling interest is $34.8 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.73%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.96%
Tags
none
Rhea-AI Summary
ProKidney Corp. has appointed Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization. Dr. Culleton brings over 20 years of experience in kidney health and will play a crucial role in the development of REACT® for chronic kidney disease (CKD) patients. Phase 3 clinical development is underway, with initial interim data expected in late 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.65%
Tags
management clinical trial
-
Rhea-AI Summary
ProKidney Corp. has announced its agreement to purchase a facility and land in Greensboro, N.C., for $25.5 million to support the future manufacturing needs of its proprietary REnal Autologous Cell Therapy. The company plans to invest in the facility through 2028 in preparation for potential commercial-scale manufacturing. ProKidney aims to submit a Biological Licensing Agreement for FDA approval of REACT in 2026, with a possible commercial launch in the U.S. later that year. The city of Greensboro and the state of North Carolina have approved an incentive package for ProKidney.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
-
Rhea-AI Summary
ProKidney Corp. to present at BofA Securities Health Care Conference 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.58%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
conferences
ProKidney Corp.

Nasdaq:PROK

PROK Rankings

PROK Stock Data

215.42M
43.48M
23.14%
60.71%
22.69%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
WINSTON-SALEM

About PROK

prokidney (nasdaq: prok), a pioneer in the treatment of ckd through innovations in cellular therapy, was founded in 2015 after a decade of research. prokidney’s lead product candidate, react™ (renal autologous cell therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of ckd, but in some cases potentially drive meaningful improvement in kidney function. late-stage ckd, stage 3b - 4, is a key target for react™ therapy. react™ has received regenerative medicine advanced therapy (rmat) designation, as well as fda and ema guidance, supporting its ongoing phase 3 clinical program, which launched in january 2022. for more information, visit www.prokidney.com.